Virta Health announced today that a study of its diabetes progression prevention treatment proved more effective than initially expected.
Peer-reviewed research in Nutrients highlighted the fact that only 3% of trial participants progressed to Type 2 diabetes, while over half achieved prediabetes reversal during the first two years, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.
The Freestyle Libre 2 from Abbott
Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history.
Attempts to manage glucose kicked off in earnest when researchers began measuring glucose in urine in the mid-1800s. Scientists’ ability to do so steadily improved over the years, but urine glucose testing wasn’t commercialized until 1908, establishing a foundation for diabetes care.
Elkhart, Ind.-based Ames Company refined the process in 1945 with the introduction of Clinitest reagent tablets, which are still commercially available, albeit from Bayer (ETR:BAYN). The company would introduce the first blood glucose test strip in 1965. The Dextrostix-branded strips were intended for use in doctors’ offices.
Get the full story on our sister site, Drug Delivery Business News.
Diabetes was already an epidemic before the novel coronavirus struck. But some researchers now suspect that COVID-19 can trigger the condition. Approximately 14% of patients with severe COVID-19 develop the disease, according to a meta-analysis recently published in the journal Diabetes, Obesity and Metabolism.
To arrive at that thesis, the researchers analyzed eight studies. Half of those came from China, while two came from Italy and two from the U.S. The diabetes rate (13.4%) was lower in the China group than the rate in the combined U.S.–Italy group (15.4%).
Get the full story from our sister site, Drug Delivery Business.
Diabetes was already an epidemic before the novel coronavirus struck. But some researchers now suspect that COVID-19 can trigger the condition. Approximately 14% of patients with severe COVID-19 develop the disease, according to a meta-analysis recently published in the journal Diabetes, Obesity and Metabolism.
To arrive at that thesis, the researchers analyzed eight studies. Half of those came from China, while two came from Italy and two from the U.S.
Researchers are uncertain why COVID-19 could cause diabetes, but they have linked infections to damage to several organs, including the lungs, heart, kidneys and brain. Some scientists are now investigating whether the disease can damage the pancreas.
The study is not the first to stipulate a link between COVID-19 and diabetes. Indeed, researchers have suspected a range of viruses can trigger type 1 diabetes. Diabetes Research and Clinical Practice and the N…
Dexcom G6 transmitter
As an early adopter of fitness trackers such as the FitBit, I’ve long appreciated the power of health data. But my recent experience with a continuous glucose monitor (CGM) has done far more to inspire me to look after my health — even as a nondiabetic.
I had heard about the potential of such technology before from the cardiologist Dr. Eric Topol, who serves on the board of Dexcom (NASDAQ:DXCM), and the entrepreneur Tim Ferriss, who has discussed using the technology as a non-diabetic to optimize weight loss and muscle gain.
But I have only recently had the chance to evaluate CGM as part of Dexcom’s “Hello Dexcom” sample program that enables patients to try out the company’s G6 CGM at no cost. The goal of the program is to increase awareness among healthcare providers and consumers.
Get the full story from our sister site, Drug Delivery Business.
As an early adopter of fitness trackers such as the FitBit, I’ve long appreciated the power of health data. But my recent experience with a continuous glucose monitor (CGM) has done far more to inspire me to look after my health — even as a nondiabetic.
I had heard about the potential of such technology before from the cardiologist Dr. Eric Topol, who serves on the board of Dexcom (NASDAQ:DXCM), and the entrepreneur Tim Ferriss, who has discussed using the technology as a non-diabetic to optimize weight loss and muscle gain.
But I have only recently had the chance to evaluate CGM as part of Dexcom’s “Hello Dexcom” sample program that enables patients to try out the company’s G6 CGM at no cost. The goal of the program is to increase awareness among healthcare providers and consumers.
Get the full story from our sister site, Drug Delivery Business.
As an early adopter of fitness trackers such as the FitBit, I’ve long appreciated the power of health data. But my recent experience with a continuous glucose monitor (CGM) has done far more to inspire me to look after my health — even as a nondiabetic.
I had heard about the potential of such technology before from the cardiologist Dr. Eric Topol, who serves on the board of Dexcom (NASDAQ:DXCM), and the entrepreneur Tim Ferriss, who has discussed using the technology as a non-diabetic to optimize weight loss and muscle gain.
But I have only recently had the chance to evaluate CGM as part of Dexcom’s “Hello Dexcom” sample program that enables patients to try out the company’s G6 CGM at no cost. The goal of the program is to increase awareness among healthcare providers and consumers.
The G6 device, pictured above, provides blood glucose readings every 5 minutes for 10 days via a smartphone app or dedicated receiver.
Brian BuntzMode…
G6 applicator from Dexcom
Continuous glucose monitors (CGMs) are among the most potent diabetes management tools to emerge in recent decades.
FDA approved the first professional CGM in 1999, and the technology has evolved swiftly since then. Current models beam data via Bluetooth to smartphones (plus the Apple Watch) and the cloud, enabling patients to explore their blood glucose readings in an app or via downloadable PDFs.
“Decades ago, we were still checking urine sugars,” said Dr. Egils Bogdanovics, a Connecticut-based endocrinologist. “In the early 1980s, fingerstick blood glucose monitors came out. That was a big deal — a revolution in diabetes,” Bogdanovics recalled.
Get the full story from our sister publication, Drug Delivery Business.
Continuous glucose monitors (CGMs) are among the most potent diabetes management tools to emerge in recent decades.
FDA approved the first professional CGM in 1999, and the technology has evolved swiftly since then. Current models beam data via Bluetooth to smartphones (plus the Apple Watch) and the cloud, enabling patients to explore their blood glucose readings in an app or via downloadable PDFs.
“Decades ago, we were still checking urine sugars,” said Dr. Egils Bogdanovics, a Connecticut-based endocrinologist. “In the early 1980s, fingerstick blood glucose monitors came out. That was a big deal — a revolution in diabetes,” Bogdanovics recalled.
Get the full story from our sister site, Drug Delivery Business.
Dexcom G6 sensor and applicator [Image from Dexcom]Continuous glucose monitors (CGMs) are among the most potent diabetes management tools to emerge in recent decades.
FDA approved the first professional CGM in 1999, and the technology has evolved swiftly since then. Current models beam data via Bluetooth to smartphones (plus the Apple Watch) and the cloud, enabling patients to explore their blood glucose readings in an app or via downloadable PDFs.
“Decades ago, we were still checking urine sugars,” said Dr. Egils Bogdanovics, a Connecticut-based endocrinologist. “In the early 1980s, fingerstick blood glucose monitors came out. That was a big deal — a revolution in diabetes,” Bogdanovics recalled.
But the fingerstick blood glucose monitor provides more of a snapshot than a moving picture. “About 15 years ago, professional continuous glucose monitoring was introduced. Initially, it was just endocrinologists [who used it], and we used it in what we called …